OXFORD, England--(BUSINESS WIRE)--Oxford Nanopore Technologies (Oxford Nanopore) today announced the launch of a new Pharmacogenomics (PGx) Beta Program to advance personalised medicine, combining Twist Bioscience’s next generation sequencing (NGS) target enrichment technology with Oxford Nanopore’s sequencing platform..

英国牛津--（商业新闻短讯）--牛津纳米孔技术公司（OXFORD Nanopore Technologies）今天宣布推出一项新的药物基因组学（PGx）测试计划，将Twist Bioscience的下一代测序（NGS）靶标富集技术与OXFORD Nanopore的测序平台相结合，以推进个性化药物。。

The newly unveiled Twist-Oxford Nanopore long-read PGx solution, which is now available for research use, is designed to provide unambiguous genetic results in a single end-to-end workflow from sample to PGx star allele call, alleviating the need for time-consuming and costly follow-up tests in contrast to conventional methods.

新推出的Twist-Oxford Nanopore long read PGx解决方案现已可供研究使用，旨在通过从样品到PGx star等位基因调用的单端到端工作流程提供明确的遗传结果，与传统方法相比，减轻了对耗时且昂贵的后续测试的需求。

The beta program aims to increase the diversity of genetic variants evaluated by Oxford Nanopore’s platform..

测试计划旨在增加牛津纳米孔平台评估的遗传变异的多样性。。

“Our collaboration with Twist Bioscience underscores our commitment to advancing the possibility of personalised medicine through PGx by providing unambiguous genetic results in a single assay,” said Gordon Sanghera, CEO of Oxford Nanopore. “Combined with Twist’s technology, Oxford Nanopore’s value proposition for PGx lies in the ability to deliver richer data through long reads, ultra-fast sequencing speed, accessible form factor and flexibility in terms of throughput, making it an ideal choice for comprehensive and efficient genetic analysis in clinical settings.'.

牛津纳米孔公司首席执行官戈登·桑格拉（GordonSanghera）表示：“我们与Twist Bioscience的合作强调了我们致力于通过单一检测提供明确的遗传结果，从而通过PGx推进个性化药物的可能性。”。“结合Twist的技术，Oxford Nanopore对PGx的价值主张在于能够通过长读取、超快速测序速度、可访问的形状因子和吞吐量方面的灵活性提供更丰富的数据，使其成为临床环境中全面有效的基因分析的理想选择。”。

The PGx beta program has successfully achieved full resolution of the CYP2D6 gene in a single assay. CYP2D6 is responsible for metabolizing 20% of drugs on the market and is one of the most challenging genes to sequence due to its complex structure. The Twist Alliance Long-Read PGx Panel coupled with Chinook, Oxford Nanopore’s CYP2D6-specific allele caller, demonstrated 100% CYP2D6 reference concordance, overcoming the limitations of conventional sequencing technologies..

PGx beta程序已在一次测定中成功实现CYP2D6基因的完全解析。CYP2D6负责代谢市场上20%的药物，由于其复杂的结构，是最具挑战性的基因之一。Twist Alliance Long Read PGx面板与牛津纳米孔公司的CYP2D6特异性等位基因调用者Chinook相结合，证明了CYP2D6参考文献的100%一致性，克服了传统测序技术的局限性。。

Key features of the PGx Beta Program include:

PGx Beta计划的主要功能包括：

Comprehensive CYP2D6 assay: Achieving full gene resolution in a single test.

全面的CYP2D6测定：在一次测试中实现完整的基因分辨率。

Integration with Oxford Nanopore devices: Twist’s Library Preparation Reagents and Target Enrichment Panels will be integrated with Oxford Nanopores’ MinION and PromethION flow cells, enabling flexibility in throughput and offering customers a seamless and powerful toolset for Oxford Nanopore sequencing..

与牛津纳米孔设备的集成：Twist的文库制备试剂和靶标富集面板将与牛津纳米孔的MinION和PromethION流动池集成，实现通量的灵活性，并为客户提供牛津纳米孔测序的无缝而强大的工具集。。

Continuous innovation and compatibility testing: Ongoing evaluations to ensure compatibility with Twist’s hybrid capture panels, including exploration of the Twist Alliance Dark Genes Panel and the Twist Exome 2.0, potentially broadening the scope of genetic research and clinical applications.

持续创新和兼容性测试：正在进行评估，以确保与Twist的杂交捕获面板兼容，包括探索Twist Alliance Dark Genes面板和Twist Exome 2.0，这可能会扩大基因研究和临床应用的范围。

“Oxford Nanopore’s technology provides genetic analysis and through our collaboration and the Pharmacogenomics Beta Program, we’re able to expand the reach of our NGS products and provide researchers with a tool to develop personalised therapies. We’re looking forward to progressing through the Beta Program and exploring additions to our collaboration,” said Emily M.

“牛津纳米孔技术提供基因分析，通过我们的合作和药物基因组学测试计划，我们能够扩大NGS产品的覆盖面，并为研究人员提供开发个性化治疗的工具。我们期待着通过测试计划取得进展，并探索我们合作的补充，”Emily M。

Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “The exceptional uniformity of our sequencer agnostic workflows enables researchers around the world to advance scientific breakthroughs.”.

Leproust博士，Twist Bioscience首席执行官兼联合创始人。“我们的测序仪不可知工作流程异常一致，使世界各地的研究人员能够推进科学突破。”。

For more information about the PGx Beta Program and other innovations from Oxford Nanopore Technologies, visit https://nanoporetech.com.

有关PGx Beta计划和牛津纳米孔技术的其他创新的更多信息，请访问https://nanoporetech.com.

About Oxford Nanopore Technologies

关于牛津纳米孔技术

Oxford Nanopore Technologies’ goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible and scalable analysis of DNA and RNA.

牛津纳米孔技术公司（Oxford Nanopore Technologies）的目标是通过使任何人、任何地方都能对任何事物进行分析，从而为社会带来最大的利益。该公司开发了新一代基于纳米孔的传感技术，用于实时，高性能，可访问和可扩展的DNA和RNA分析。

The technology is used in more than 120 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes..

这项技术已在120多个国家使用，以了解人类生物学以及癌症、植物、动物、细菌、病毒和整个环境等疾病。Oxford Nanopore Technologies产品用于分子生物学应用，不用于诊断目的。。